Genetic Counseling: Preconception, Prenatal and Perinatal

Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment: Sixth Edition

Volumn , Issue , 2010, Pages 1-62

  Milunsky, Aubrey ^a   Milunsky, Jeff M ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Congenital malformations and structural defects; Genetic counseling preconception, prenatal and perinatal; Genetic disorders and congenital malformations; Identification of mutations serious fatal monogenic genetic disorders; Mainz Birth Defects Registry in Germany, 1998 malformations, livebirths, stillbirths and abortions; Molecular diagnostics and fetal imaging predictive, preimplantation and prenatal diagnosis; Molecular genetics and fetal imaging advances securing early prenatal diagnosis; Preconception genetic counseling prelude to prenatal diagnosis; Prenatal genetic diagnosis and reassurance to couples at risk; Somatic cell mosaicism with mutations in hypomelanosis of Ito

Indexed keywords

EID: 84886527147     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444314342.ch1     Document Type: Chapter

References (478)

1. Martin RH, Ko E, Rademaker A. Distribution ofaneuploidy in human gametes:comparison betweenhuman sperm and oocytes. Am J Med Genet 1991;39:321.
2. Plachot M. Chromosome analysis of oocytes andembryos. In:Verlinsky Y, Kuliev A, eds. Preimplantationgenetics. New York:Plenum Press, 1991:103.
3. BouéJ, BouéA, Lazar P. Retrospective and prospectiveepidemiological studies of 1500 karyotyped spontaneoushuman abortions. Teratology 1975;12:11.
4. Alberman ED, Creasy MR. Frequency of chromosomalabnormalities in miscarriages and perinatal deaths. JMed Genet 1977;14:313.
5. Holmes-Seidle M, Ryyvanen M, Lindenbaum RH. Parental decisions regarding termination of pregnancyfollowing prenatal detection of sex chromosomeabnormality. Prenat Diagn 1987;7:239.
6. Martinez-Frias ML, Bermejo E, Cereijo A, et al. Epidemiologicalaspects of Mendelian syndromes in aSpanish population sample. II. Autosomal recessivemalformation syndromes. Am J Med Genet 1991;38:626.
7. Njoh J, Chellaram R, Ramas L. Congenital abnormalitiesin Liberian neonates. West Afr J Med 1991;10:439.
8. Verma IC. Burden of genetic disorders in India. IndianJ Pediatr 2001;67:893.
9. Lie RT, Wilcox AJ, Skjaerven R. Survival and reproductionamong males with birth defects and risk ofrecurrence in their children. JAMA 2001;285:755.
10. Queisser-Luft A, Stolz G, Wiesel A, et al. Malformationsin newborn:results based on 30,940 infants andfetuses from the Mainz congenital birth defect monitoringsystem (1990-1998). Arch Gynecol Obstet 2002;266:163.
11. McKusick VA. Mendelian inheritance in man, 12th ed.Baltimore:Johns Hopkins University Press, 1998.
12. Baird PA, Anderson TW, Newcombe HB, et al. Geneticdisorders in children and young adults:a populationstudy. Am J Hum Genet 1988;42:677.
13. Milunsky A. The prevention of genetic disease andmental retardation. Philadelphia:WB Saunders, 1975.
14. Myrianthopoulos NC. Malformations in children fromone to seven years. New York:Alan R. Liss, 1985.
15. Braverman AC, Göven H, Beardslee MA, et al. Thebicuspid aortic valve. Curr Probl Cardiol 2005;30:470.
16. Williams DS. Bicuspid aortic valve. J Insur Med 2006;38:72.
17. Reller MD, Strickland MJ, Riehle-Colarusso T, et al. Prevalence of congenital heart defects in metropolitanAtlanta, 1998-2005. J Pediatr 2008;153:807.
18. Galjaard H. Genetic metabolic diseases:early diagnosisand prenatal analysis. Amsterdam:Elsevier/North-Holland , 1980.
19. Scriver CR, Neal JL, Saginur R, et al. The frequency ofgenetic disease and congenital malformation amongpatients in a pediatric hospital. Can Med Assoc J 1973;108:1111.
20. Brent RL. The magnitude of the problem of congenitalmalformations. In:Marois M, ed. Prevention of physicaland mental congenital defects. Part A:The scope ofthe problem. New York:Alan R. Liss, 1985:55.
21. Brent R. Environmental causes of human congenitalmalformations. Prog Obstet Gyncecol 2008;5:61.
22. Stoll C, Alembik Y, Dott B, et al. Impact of prenataldiagnosis on livebirth prevalence of children with congenitalanomalies. Ann Genet 2002;45;115.
23. de Vigan C, Khoshnood B, Cadio E, et al. Prenataldiagnosis and prevalence of Down syndrome in theParisian population, 2001-2005. Gynecol Obstet Fertil 2008;36:146.
24. Rankin J, Glinianaia S, Brown R, Renwick M. Thechanging prevalence of neural tube defects:a population-based study in the north of England, 1984-96.Northern Congenital Abnormality Survey SteeringGroup. Paediatr Perinat Epidemiol 2000;14:104.
25. Iliyasu Z, Gilmour WH, Stone DH. Prevalence ofDown syndrome in Glasgow, 1980-96:the growingimpact of prenatal diagnosis on younger mothers. Health Bull (Edinb) 2002;60:20.
26. Weijerman ME, van Furth AM, Vonk Noordegraaf A,et al. Prevalence, neonatal characteristics and first-yearmortality of Down syndrome:a national study. JPediatr 2008;152:15.
27. Besser LM, Shin M, Kucik JE, et al. Prevalence of Downsyndrome among children and adolescents in metropolitanAtlanta. Birth Defects Res A Clin Mol Teratol 2007;79:765.
28. Milunsky A, Jick H, Jick SS, et al. Multivitamin/folicacid supplementation in the earliest weeks of pregnancy reduces the prevalence of neural tube defects.JAMA 1989;262:2847.
29. MRC Vitamin Study Research Group. Prevention ofneural tube defects:results of the Medical ResearchCouncil Vitamin Study. Lancet 1991;338:131.
30. Ray JG, Meier C, Vermeulen MJ, et al. Association ofneural tube defects and folic acid food fortification inCanada. Lancet 2002;360:2047.
31. Rasmussen SA, Moore CA, Paulozzi LJ, et al. Risk forbirth defects among premature infants:a population-based study. J Pediatr 2001;138:668.
32. Glinianaia SV, Rankin J, Wright C. Congenital anomaliesin twins:a register-based study. Hum Reprod 2008;23:1306.
33. Woods CG, Cox J, Springell K, et al. Quantification ofhomozygosity in consanguineous individuals withautosomal recessive disease. Am J Hum Genet 2006;78:889.
34. Hoffman JI, Kaplan S. The incidence of congenitalheart disease. J Am Coll Cardiol 2002;39:1890.
35. Stothard KJ, Tennant PW, Bell R, et al. Maternal overweightand obesity and the risk of congenital anomalies:a systematic review and meta-analysis. JAMA 2009;301:636.
36. Watkins ML, Rasmussen SA, Honein MA, et al. Maternalobesity and risk for birth defects. Pediatrics 2003;111:1152.
37. Shaw GM, Todoroff K, Finnell RH, et al. Spina bifidaphenotypes in infants or fetuses of obese mothers. Teratology 2000;61:376.
38. Moore LL, Singer MR, Bradlee ML, et al. A prospectivestudy of the risk of congenital defects associated withmaternal obesity and diabetes mellitus. Epidemiology 2000;11:689.
39. Moore LL, Bradlee ML, Singer MR, et al. Chromosomalanomalies among the offspring of women withgestational diabetes. Am J Epidemiol 2002;155:719.
40. Lam PK, Torfs C, Brand RJ. A low pregnancy bodymass index is a risk factor for an offspring with gastroschisis.Epidemiology 1999;10(6):717-21.38a. Vu LT, Nobuhara KK, Laurent C, et al. Increasingprevalence of gastroschisis:population-based study inCalifornia. J Pediatr 2008;152:807.
41. Stoll C, Dott B, Alembik Y, et al. Congenital anomaliesassociated with congenital hypothyroidism. Ann Genet 1999;42:17.
42. Olafsson E, Hallgrimsson JT, Hauser WA, et al. Pregnanciesof women with epilepsy:a population-basedstudy in Ireland. Epilepsia 1998;39:887.
43. Kjaer D, Horvath-PuhóE, Christensen J, et al. Antiepilepticdrug use, folic acid supplementation and congenitalabnormalities:a population-based case-controlstudy. Br J Obstet Gynaecol 2008;115:98.
44. Kung HC, Hoyert DL, Xu J, et al. Deaths:final data for2005. Natl Vital Stat Rep. 2008;56:1.
45. Rasmussen SA, Wong LY, Yang Q, et al. Population-based analyses of mortality in trisomy 13 and trisomy18. Pediatrics 2003;111:777.
46. DeGalan-Roosen AE, Kuijpers JC, Meershoek AP, et al. Contribution of congenital malformations to perinatalmortality:a 10 years prospective regional study in TheNetherlands. Eur J Obstet Gynecol Reprod Biol 1998;80:55.
47. Dastgiri S, Gilmour WH, Stone DH. Survival of childrenborn with congenital anomalies. Arch Dis Child 2003;88:391.
48. Liu S, Joseph KS, Wen SW. Trends in fetal and infantdeaths caused by congenital anomalies. Semin Perinatol 2002;26:268.
49. Masaki M, Higurashi M, Iijima K, et al. Mortality andsurvival for Down syndrome in Japan. Am J HumGenet 1981;33:629.
50. Dupont A, Vaeth M, Videbech P. Mortality and lifeexpectancy of Down's syndrome in Denmark. J MentDefic Res 1986;30:111.
51. Fryers T. Survival in Down's syndrome. J Ment Defic Res 1986;30:101.
52. Malone Q. Mortality and survival of the Down's syndromepopulation in Western Australia. J Ment Defic Res 1988;32:59.
53. Baird PA, Sadovnick AD. Life expectancy in Down syndromeadults. Lancet 1988;2:1354.
54. Baird PA, Sadovnick AD. Life expectancy in Down syndrome. J Pediatr 1987;110:849.
55. Baird PA, Sadovnick AD. Life tables for Down syndrome. Hum Genet 1989;82:291.
56. Strauss D, Eyman RK. Mortality of people with mentalretardation in California with and without Down syndrome,1986-1991. Am J Ment Retard 1996;100:643.
57. Yang Q, Rasmussen SA, Friedman JM. Mortality associatedwith Down's syndrome in the USA from 1983to 1997:a population-based study. Lancet 2002;359:1019.
58. Hasle H, Clemmensen IH, Mikkelsen M. Risks ofleukemia and solid tumours in individuals withDown's syndrome. Lancet 2000;355:165.
59. Roizen NJ, Patterson D. Down's syndrome. Lancet 2003;361:1281.
60. Matsunaga S, Imakiire T, Koga H, et al. Occult spinalcanal stenosis due to C-1 hypoplasia in children withDown syndrome. J Neurosurg 2007;107:457.
61. Anwar AJ, Walker JD, Frier BM. Type 1 diabetes mellitusand Down's syndrome:prevalence, managementand diabetic complications. Diabet Med 1998;15:160.
62. Menéndez M. Down syndrome, Alzheimer's diseaseand seizures. Brain Dev 2005;27:246.
63. Patja K, Pukkala E, Sund R, et al. Cancer incidence ofpersons with Down syndrome in Finland:a population-based study. Int J Cancer 2006;118:1769.
64. Hill DA, Gridley G, Cnattingius S, et al. Mortality andcancer incidence among individuals with Down syndrome. Arch Intern Med 2003;163:705.
65. Glasson EJ, Sullivan SG, Hussain R, et al. The changingsurvival profile of people with Down's syndrome:implicationsfor genetic counseling. Clin Genet 2002;62:390.
66. Halliday J, Collins V, Riley M, et al. Has prenatalscreening influcenced the prevalence of comorbidibitesassociated with Down syndrome and subsequent survivalrates? Pediatrics 2009;123:256.
67. Zigman WB, Lott IT. Alzheimer's disease in Down syndrome:neurobiology and risk. Ment Retard DevDisabil Res Rev 2007;13:237.
68. Menéndez M. Down syndrome, Alzheimer's diseaseand seizures. Brain Dev 2005;27:246.
69. Milunsky A. The prenatal diagnosis of hereditary disorders.Springfield, IL:Charles C. Thomas, 1973.
70. Rubin SP, Malin J, Maidman J. Genetic counselingbefore prenatal diagnosis for advanced maternal age:an important medical safeguard. Obstet Gynecol 1983;62:155.
71. Tóth A, Nyάri T, SzabóJ. Changing views on the goalof reproductive genetic counselling in Hungary. Eur JObstet Gyncecol Reprod Biol 2008;137:3.
72. Kessler S. Psychological aspects of genetic counseling.XIII. Empathy and decency. J Genet Couns 1999;8:333.
73. Harris R, Lane B, Harris H, et al. National ConfidentialEnquiry into counseling for genetic disorders by non-geneticists:general recommendations and specific standards for improving care. Br J Obstet Gynaecol 1999;106:658.
74. van Langen IM, Birnie E, Leschot NJ, et al. Geneticknowledge and counseling skills of Dutch cardiologists:sufficient for the genomics era? Eur Heart J 2003;24:560.
75. Rosas-Blum E, Shirsat P, Leiner M. Communicatinggenetic information:a difficult challenge for futurepediatricians. BMC Med Educ 2007;7:17.
76. Harvey EK, Fogel CE, Peyrot M, et al. Providers'knowledge of genetics:a survey of 5915 individuals andfamilies with genetic conditions. Genet Med 2007;9:259.
77. Baars MJ, Henneman L, Ten Kate LP. Deficiency ofknowledge of genetics and genetic tests among generalpractitioners, gynecologists and pediatricians:a globalproblem. Genet Med 2005;7:605.
78. Shaer CM, Chescheir N, Erickson K, et al. Obstetrician-gynecologists'practice and knowledge regardingspina bifida. Am J Perinatol 2006;23:355.
79. Gordis L, Childs B, Roseman MG. Obstetricians'attitudestoward genetic screening. Am J Public Health 1977;67:469.
80. Kessler S. Psychological aspects of genetic counseling.XII. More on counseling skills. J Genet Couns 1998;7:263.
81. Milunsky A, Annas GJ. Genetics and the law. NewYork: Plenum Press, 1976.
82. Milunsky A, Annas GJ. Genetics and the law II. NewYork: Plenum Press, 1980.
83. Milunsky A, Annas GJ. Genetics and the law III. NewYork: Plenum Press, 1985.
84. Lewis C, Mehta P, Kent A, et al. An assessment ofwritten patient information provided at the geneticclinic and relating to genetic testing in seven Europeancountries. Eur J Hum Genet 2007;15:1012.
85. Levetown M and the Committee on Bioethics. Communicatingwith children and families:from everydayinteractions to skill in conveying distressing information. Pediatrics 2008;121:e 1441.
86. Working Party of the Royal College of Physicians. Improving communication between doctors andpatients. J R Coll Physicians Lond 1997;31:258.
87. Forrest LE, Delatycki MB, Skene L, et al. Communicatinggenetic information in families-a review ofguidelines and position papers. Eur J Hum Genet 2007;15:612.
88. Farrell M, Deuster L, Donovan J, et al. Pediatric residents'use of jargon during counseling about newborngenetic screening results. Pediatrics 2008;122:243.
89. Welkenhuysen M, Evers-Kiebooms G, d'Ydewalle G. The language of uncertainty in genetic risk communication:framing and verbal versus numerical information. Patient Educ Couns 2001;43:179.
90. Benkendorf JL, Prince MB, Rose MA, et al. Does indirect speech promote nondirective genetic counseling? Results of a sociolinguistic investigation. Am J Med Genet 2001;106:199.
91. Abramsky L, Fletcher O. Interpreting information:what is said, what is heard:a questionnaire study ofhealth professionals and members of the public. PrenatDiagn 2002;22:1188.
92. O'Doherty K, Suthers GK. Risky communication:pitfallsin counseling about risk and how to avoid them. J Genet Couns 2007;16:409.
93. Palermo GD, Colombero LT, Schattman GL, et al. Evolutionof pregnancies and initial follow-up of newbornsdelivered after intracytoplasmic sperm injection.JAMA 1996;276:1893.
94. Girardi SK, Schlegel PN. Microsurgical epididymalsperm aspiration:review of techniques, preoperativeconsiderations and results. J Androl 1996;17:5.
95. Looi JCL. Empathy and competence. Med J Aust2008;188:414.
96. Eden OB, Black I, MacKinlay GA, et al. Communicationwith parents of children with cancer. Palliat Med 1994;8:105.
97. Turner J, Biesecker B, Leib J, et al. Parenting childrenwith Proteus syndrome:experiences with, and adaptationto, courtesy stigma. Am J Med Genet A 2007;143A:2089.
98. Hojat M, Mangione S, Nasca TJ, et al. The JeffersonScale of Physician Empathy:development and preliminarypsychomatric data. Educ Psychol Meas 2001;61:349.
99. Stoll C, Alembik Y, Dott B, et al. Omphalocele andgastroschisis and associated malformations. Am J MedGenet A 2008;146A:1280.
100. James CA, Hadley DW, Holtzman NA, et al. How doesthe mode of inheritance of a genetic condition influencefamilies? A study of guilt, blame, stigma andunderstanding of inheritance and reproductive risks infamilies with X-linked and autosomal recessive diseases. Genet Med 2006;8:234.
101. Targum SD. Psychotherapeutic considerations ingenetic counseling. Am J Med Genet 1981;8:281.
102. Kessler S, Kessler H, Ward P. Psychological aspects ofgenetic counseling. III. Management of guilt andshame. Am J Med Genet 1984;17:673.
103. Hayden MR, Canadian Collaborative Study of Predictive Testing for HD. Predictive medicine for late onsetdisorders:the experience for Huntington disease. Am J Hum Genet 1991;49:50.
104. Tibben A, Vegter-van der Vlis M, Skraastad MI, et al. Presymptomatic DNA-testing for Huntington diseasein The Netherlands. Am J Hum Genet 1991;49:316.
105. Craufurd D, Dodge A, Kerzin-Storrar L, et al. Psychosocialimpact of presymptomatic predictive testingfor Huntington's disease. Am J Hum Genet 1991;49:311.
106. Huggins M, Bloch M, Kanani S, et al. Ethical and legaldilemmas arising during predictive testing for adult-onset disease:the experience of Huntington disease. Am J Hum Genet 1990;47:4.
107. Folstein SE. Presymptomatic testing for Huntington'sdisease:outcome of 136 at-risk persons who requestedtesting. Am J Hum Genet 1991;49:62.
108. Wiggins S, Whyte P, Hayden M, et al. No harm, potentialbenefit:the one year follow-up of participants inthe Canadian Collaborative Study of Predictive Testingfor Huntington's Disease. Am J Hum Genet 1991;49:317.
109. Ravine D, Walker RG, Sheffield JL, et al. Experience offamily screening for autosomal dominant polycystickidney disease. Am J Hum Genet 1991;49:50.
110. Baumiller RC, Comley S, Cunningham G, et al. Codeof ethical principles for genetics professionals. Am JMed Genet 1996;65:177.
111. Baumiller RC, Cunningham G, Fisher N, et al. Code ofethical principles for genetics professionals:an explication. Am J Med Genet 1996:65:179.
112. Rantanen E, Hietala M, Kristoffersson U, et al. What isideal genetic counseling? A survey of current international guidelines. Eur J Hum Genet 2008;16:445.
113. Brown RH Jr. Dystrophin-associated proteins and themuscular dystrophies. Annu Rev Med 1997;48:457.
114. Weber YG, Lerche H. Genetic mechanisms in idiopathicepilepsies. Dev Med Child Neurol 2008;50:648.
115. Guerrini R, Casari G, Marini C. The genetic andmolecular basis of epilepsy. Trends Mol Med 2003;9:300.
116. Chang BS, Lowenstein DH. Epilepsy. N Engl J Med 2003;349:1257.
117. Passos-Bueno MR, Serti Eacute AE, Jehee FS, et al. Genetics of craniosynostosis:genes, syndromes, mutationsand genotype-phenotype correlations. Front OralBiol 2008;12:107.
118. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008;372:657.
119. Rossetti S, Harris PC. Genotype-phenotype correlationsin autosomal dominant and autosomal recessivepolycystic kidney disease. J Am Soc Nephrol 2007;18:1374.
120. Bergmann C, Brüchle NO, Frank V, et al. Perinataldeaths in a family with autosomal dominant polycystickidney disease and a PKD2 mutation. N Engl J Med 2008;359:318.
121. Rasmussen SA, Mulinare J, Khoury MJ, et al. Evaluationof birth defect histories obtained through maternalinterviews. Am J Hum Genet 1990;46:478.
122. Haxton MJ, Bell J. Fetal anatomical abnormalities andother associated factors in middle-trimester abortionand their relevance to patient counseling. Br J ObstetGynaecol 1983;90:501.
123. Harper PS. Myotonic dystrophy, 2nd edn. London: WB Saunders, 1989.
124. Bergoffen J, Kant J, Sladky J, et al. Paternal transmissionof congenital myotonic dystrophy. J Med Genet 1994;31:518.
125. Wieringa B. Myotonic dystrophy reviewed:back to thefuture? Hum Mol Genet 1994;3:1.
126. Shelbourne P, Winqvist R, Kunert E, et al. UnstableDNA may be responsible for the incomplete penetranceof the myotonic dystrophy phenotype. HumMol Genet 1992;1:467.
127. Brunner HG, Jansen G, Nillesen W, et al. Reversemutation in myotonic dystrophy. N Engl J Med 1993;328:476.
128. O'Hoy KL, Tsilfidis C, Mahadevan MS, et al. Reductionin size of the myotonic dystrophy trinucleotiderepeat mutation during transmission. Science 1993;259:809.
129. Brook JD. Retreat of the triplet repeat? Nat Genet 1993;3:279.
130. Hunter AG, Jacob P, O'Hoy K, et al. Decrease in thesize of the myotonic dystrophy CTG repeat duringtransmission from parent to child:implications forgenetic counseling and genetic anticipation. Am J MedGenet 1993;45:401.
131. Ashizawa T, Anvret M, Baiget M, et al. Characteristicsof intergenerational contractions of the CTG repeat inmyotonic dystrophy. Am J Hum Genet 1994;54:414.
132. Abeliovich D, Lerer I, Pashut-Lavon I, et al. Negativeexpansion of the myotonic dystrophy unstablesequence. Am J Hum Genet 1993;52:1175.
133. Ashizawa T, Dunne PW, Ward PA, et al. Effects of thesex of myotonic dystrophy patients on the unstabletriplet repeat in their affected offspring. Neurology 1994;44:120.
134. Anvret M, Ahlberg G, Grandell U, et al. Larger expansionsof the CTG repeat in muscle compared to lymphocytesfrom patients with myotonic dystrophy. Hum Mol Genet 1993;2:1397.
135. Thornton CA, Griggs R, Moxley RT. Myotonic dystrophywith no trinucleotide repeat expansion. AnnNeurol 1994;35:269.
136. Milunsky A, Skare JC, Milunsky JM, et al. Prenataldiagnosis of myotonic muscular dystrophy with DNAprobes. Am J Obstet Gynecol 1991;164:751.
137. Moore RC, Xiang F, Monaghan J et al. Huntingtondisease phenocopy is a familial prion disease. Am JHum Genet 2001;69:1385.
138. Creighton S, Almqvist EW, MacGregor D, et al. Predictive,pre-natal and diagnostic genetic testing for Huntington's disease:the experience in Canada from 1987to 2000. Clin Genet 2003;63:462.
139. Stevanin G, Camuzat A, Holmes SE, et al. CAG/CTGrepeat expansions at the Huntington's disease-like 2locus are rare in Huntington's disease patients. Neurology 2002;58:965.
140. Voutoufianakis S, Psoni S, Vorgia P, et al. Coinheritanceof mutated SMN1and MECP2 genes in a childwith phenotypic features of spinal muscular atrophy(SMA) type II and Rett syndrome. Eur J PaediatrNeurol 2007;11:235.
141. Fraser FC. Genetic counseling. Am J Hum Genet 1974;26:636.
142. Clow CL, Fraser C, Laberge C, et al. On the applicationof knowledge to the patient with genetic disease. In:Steinberg AG, Bearn AG, eds. Progress in medical genetics,vol. 9. New York:Grune and Stratton, 1979:159.
143. Shaw MW. Genetic counseling. Science 1974;184:751.
144. Emery AEH. Genetic counseling. BMJ 1975;3:219.
145. World Health Organization Expert Committee. Genetic counseling. WHO Tech Rep 1969;416:1.
146. Wertz DC, Fletcher JC. Attitudes of genetic counselors:a multinational survey. Am J Hum Genet 1988;42:592.
147. Wertz DC, Fletcher JC, Mulvihill JJ. Medical geneticistsconfront ethical dilemmas:cross-cultural comparisonsamong 18 nations. Am J Hum Genet 1990;46:1200.
148. Kessler S. Psychological aspects of genetic counseling.XI. Nondirectiveness revisited. Am J Med Genet 1997;72:164.
149. Hsia YE. Choosing my children's genes:genetic counseling. In:Lipkin M, Rowley PT, eds. Genetic responsibility. New York:Plenum Press, 1974:43.
150. Sorenson JR, Culbert AF. Counselors and counselingorientations:unexamined topics in evaluation. In:Lubs HA, de la Cruz F, eds. Genetic counseling. NewYork: Raven Press, 1977:131.
151. Michie S, Bron F, Bobrow M, et al. Nondirectivenessin genetic counseling:an empirical study. Am J HumGenet 1997;60:40.
152. Clarke A. Is non-directive genetic counseling possible? Lancet 1991;338:998.
153. Milunsky A, Littlefield JW, Kanfer JN, et al. Prenatalgenetic diagnosis. N Engl J Med 1970;283:1370, 1441,1498.
154. Super M. Non-directive genetic counseling. Lancet 1991;338:1266.
155. Pembrey M. Non-directive genetic counseling. Lancet 1991;338:1267.
156. Harris R, Hopkins A. Non-directive genetic counseling. Lancet 1991;338:1268.
157. Clarke A. Non-directive genetic counseling. Lancet 1991;338:1524.
158. Einhorn HJ, Hogarth RM. Behavioral decision theory:processes of judgment and choice. Annu Rev Psychol 1981;32:53.
159. Simms M. Informed dissent:the view of some mothersof severely mentally handicapped young adults. J MedEthics 1986;12:72.
160. Simms M. Non-directive genetic counseling. Lancet 1991;338:1268.
161. Keeling SL. Duty to warn of genetic harm in breach ofpatient confidentiality. J Law Med 2004;12:235.
162. Carnevale A, Lisker R, Villa AR, et al. Counseling followingdiagnosis of a fetal abnormality:comparison ofdifferent clinical specialists in Mexico. Am J Med Genet 1997;69:23.
163. Williams C, Alderson P, Farsides B. Is nondirectivenesspossible within the context of antenatal screening andtesting? Soc Sci Med 2002;54:339.
164. Chapman MA. Predictive testing for adult-onsetgenetic disease:ethical and legal implications of the useof linkage analysis for Huntington disease. Am J HumGenet 1990;47:1.
165. Marteau TM, Nippert I, Hall S, et al. Outcomes ofpregnancies diagnosed with Klinefelter syndrome:thepossible influence of health professionals. PrenatDiagn 2002;22:562.
166. Knoppers BM, Joly Y, Simard J, et al. The emergenceof an ethical duty to disclose genetic research results:international perspectives. Eur J Hum Genet 2006;14:1170.
167. Katz J. The silent world of doctor and patient. New York: Free Press, 1984.
168. Lantos JD. Should we always tell children the truth? Perspect Biol Med 1996;40:78.
169. Capron AM. Autonomy, confidentiality and qualitycare in genetic counseling. In:Capron AM, Lappe M,Murray RF, et al., eds. Genetic counseling:facts, valuesand norms. New York:Alan R. Liss, 1979:307.
170. Rosenthal MS, Pierce HH. Inherited medullary thyroidcancer and the duty to warn:revisiting Pate v. Threlkelin light of HIPAA. Thyroid 2005;15:140.
171. Suthers GK, Armstrong J, McCormack J, et al. Lettingthe family know:balancing ethics and effectivenesswhen notifying relatives about genetic testing for afamilial disorder. J Med Genet 2006;43:665.
172. AMA Policy H-140.899. Disclosure of familial risk ingenetic testing. In: Code of medical ethics. Chicago: American Medical Association, 2003.
173. Tarasoff v. Regents of Univ. of Cal., 17 Cal.3d 425,131Cal.Rptr 14,551 P.2d 334 (1976).
174. Davis v. Lhim, 124 Mich.App.291, 335 N.W.2d 481(1983).
175. ASHG statement. Professional disclosure of familialgenetic information. The American Society of HumanGenetics Social Issues Subcommittee on Familial Disclosure.Am J Hum Genet 1998;62:474.
176. Falk MJ, Dugan RB, O'Riordan MA, et al. Medicalgeneticists'duty to warn at-risk relatives for geneticdisease. Am J Med Genet 2003;120 A:374.
177. Milunsky A. Genetic disorders and the fetus:diagnosis,prevention and treatment, 2nd edn. New York:PlenumPress, 1986.
178. Milunsky A. Know your genes. Boston, MA:Houghton-Miffl in, 1977.
179. Hsia YE, Hirschhorn K, Silverberg RL, et al. Counselingin genetics. New York:Alan R. Liss, 1979.
180. Frets PG. The reproductive decision after geneticcounseling. PhD thesis. Rotterdam:Erasmus University,1990.
181. Milunsky A. How to have the healthiest baby you can. New York: Simon & Schuster, 1987.
182. Milunsky A. Choices, not chances:an essential guideto your heredity and health. Boston, MA:Little, Brown,1989.
183. Milunsky A. Heredity and your family's health. Baltimore, MD:Johns Hopkins University Press,1992.
184. Cantebury v. Spence, 464 F.2d 772 (D.C. Cir. 1972).
185. Pelias MZ. Duty to disclose in medical genetics:a legalperspective. Am J Med Genet 1991;39:347.
186. Hirschhorn K, Fleischer LD, Godmilow L, et al. Dutyto re-contact. Genet Med 1999;1:171.
187. Hunter AG, Sharpe N, Mullen M, et al. Ethical, legaland practical concerns about recontacting patient toinform them of new information:the case in medicalgenetics. Am J Med Genet 2001;103:265.
188. Mink v. University of Chicago, 460F.Supp.713(N.D.Ill. 1978).
189. Tresemer v. Barke, 86 Cal.App.3d 656, 150 Cal.Rptr 384 (1978).
190. Committee of the International Huntington Associationand the World Federation of Neurology. Guidelinesfor the molecular genetics predictive test inHuntington's disease. J Med Genet 1994;31:555.
191. Jones EF, Forrest JD, Henshaw SK, et al. Unintendedpregnancy, contraceptive practice and family planningservices in developed countries. Fam Plann Perspect 1988;20:53.
192. Lucast EK. Informed consent and the misattributedpaternity problem in genetic counseling. Bioethics 2007;21:41.
193. Weil J, Ormond K, Peters J, et al. The relationship ofnondirectiveness to genetic counseling:report of aworkshop at the 2003 NSGC Annual Education Conference. J Genet Couns 2006;15:85.
194. Tan HL, Hofman N, van Langen IM, et al. Suddenunexplained death. Heritability and diagnostic yield ofcardiological and genetic examination in survivingrelatives. Circulation 2005;112:207.
195. Heyes T, Long S, Mathers N. Preconception care:practiceand beliefs of primary care workers. Fam Pract 2004;21:22.
196. Czeizel AE, Gasztonyi Z, Kuliev A. Periconceptionalclinics:a medical health care infrastructure of newgenetics. Fetal Diagn. Ther 2005;20:515.
197. Solomon BD, Jack BW, Feero WG. The clinical contentof preconception care:genetics and genomics. Am JObstet Gynecol 2008;199:S 340.
198. Hollier LM, Leveno KJ, Kelly MA, et al. Maternal ageand malformations in singleton births. Obstet Gynecol 2000;96:701.
199. Cnossen MH, Smit FJ, deGoede-Bolder A, et al. Diagnosticdelay in neurofibromatosis type 1. Eur J Pediatr 1997;156:482.
200. Wilkins-Haug L, Quade B, Morton CC. Confined placentalmosaicism as a risk factor among newborns withfetal growth restriction. Prenat Diagn 2006;26:428.
201. Spence JE, Perciaccante RG, Greig GM, et al. Uniparentaldisomy as a mechanism for human geneticdisease. Am J Hum Genet 1988;42:217.
202. Nicholls RD, Knoll JHM, Butler MG, et al. Geneticimprinting suggested by maternal uniparental heterodisomyin nondeletion Prader-Willi syndrome. Nature 1989;342:281.
203. Malcolm S, Clayton-Smith J, Nichols M, et al. Uniparentalpaternal disomy in Angelman's syndrome. Lancet 1991;337:694.
204. Brzustowicz LM, Alitto BA, Matseoane D, et al. Paternal isodisomy for chromosome 5 in a child withspinal muscular atrophy. Am J Hum Genet 1994;54:482.
205. Kalousek DK, Barrett I. Genomic imprintingrelated to prenatal diagnosis. Prenat Diagn 1994;14:1191.
206. Ledbetter DH, Engel E. Uniparental disomy in humans:development of an imprinting map and its implicationsfor prenatal diagnosis. Hum Mol Genet 1995;4:1757.
207. Milunsky JM, Maher T, Lebo R, et al. Prenatal diagnosisfor Schmid metaphyseal chondrodysplasia in twins. Fetal Diagn Ther 1998;13:167.
208. Milunsky A, Ito M, Maher TA, et al. Prenatal moleculardiagnosis of tuberous sclerosis complex. Am J ObstetGynecol 2009;200 (3):321.
209. Milunsky A, Konialis C, Shim SH, et al. The prenataldiagnosis of cerebral autosomal dominant arteriopathywith subcortical infarcts and leukoencephalopathy(CADASIL) by mutation analysis. Prenat Diagn 2005;25:1057.
210. Konialis C, Hagnefelt B, Kokkali G, et al. Pregnancyfollowing preimplantation genetic diagnosis of cerebralautosomal dominant arteriopathy with subcortical infarctsand leukoencephalopathy (CADASIL). PrenatDiagn 2007;27:1079.
211. Middleton A, Hewison J, Mueller R. Prenatal diagnosisfor inherited deafness:what is the potential demand? JGenet Couns 2001;10:121.
212. Horwich AL, Fenton WA. Precarious balance of nitrogenmetabolism in women with a urea-cycle defect. NEngl J Med 1990;322:1668.
213. Parris WCV, Quimby CW. Anesthetic considerationsfor the patient with homocystinuria. Anesth Analg 1982;61:708.
214. Lipscomb KJ, Smith JC, Clarke B, et al. Outcome ofpregnancy in women with Marfan's syndrome. Br JObstet Gynaecol 1997;104:201.
215. Milewicz DM, Dietz HC, Miller DC. Treatment ofaortic disease in patients with Marfan syndrome. Circulation 2005;111:e 150.
216. Pacini L, Digne F, Boumendil A, et al. Maternal complicationof pregnancy in Marfan syndrome. Int JCardiol. 2008;July 14 (Epub ahead of print).
217. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromescaused by mutations in the TGF-beta receptor. N Engl J Med 2006;355:788.
218. Meijboom LJ, Drenthen W, Pieper PG, et al. Obstetriccomplications in Marfan syndrome. Int J Cardiol 2006;110:53.
219. Murdoch JL, Walker BA, Halpern BL, et al. Life expectancyand causes of death in the Marfan syndrome. NEngl J Med 1972;286:804.
220. Shores J, Berger K, Murphy E, et al. Progression ofaortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl JMed 1994;330:1335.
221. Brooke BS, Habashi JP, Judge DP, et al. Angiotensin IIblockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008;358:2787.
222. Lacro RV, Dietz HC, Wruck LM, et al. Rationale anddesign of a randomized clinical trial of beta-blockertherapy (atenolol) versus angiotensin II receptorblocker therapy (losartan) in individuals with Marfansyndrome. Am Heart J 2007;154:624.
223. McMullen AH, Pasta DJ, Frederick PD, et al. Impactof pregnancy on women withcystic fibrosis. Chest 2006;129:706.
224. Clinton MJ, Nierderman MS, Matthay RA. Maternalpulmonary disorders complicating pregnancy. In Reece EA, Hobbins JC, Mahoney MJ, et al., eds. Medicineof the fetus and mother. Philadelphia:JB Lippincott, 1992:955.
225. Dugoff L, Sujansky E. Neurofibromatosis type 1 andpregnancy. Am J Med Genet 1996;66:7.
226. Riccardi VM, Mulvihill JJ. Advances in neurology:neurofibromatosis (von Recklinghausen disease). NewYork: Raven Press, 1981:95.
227. Jaffe R, Mock M, Abramowicz J. Myotonic dystrophyand pregnancy:a review. Obstet Gynecol Surv 1986;31:272.
228. Kadir RA, Economides DL, Braithwaite J, et al. Theobstetric experience of carriers of haemophilia. Br JObstet Gynaecol 1997;104:7:803.
229. Pennell PB. Pregnancy in the woman with epilepsy:maternal and fetal outcomes. Semin Neurol 2002;22:299.
230. Chamcides L, Truex RC, Vetter V, et al. Association ofmaternal systemic lupus erythematosus and congenitalcomplete heart block. N Engl J Med 1977;297:1204.
231. Lopes LM, Tavares GM, Damiano AP, et al. Perinataloutcome of fetal atrioventricular block:one-hundred-sixteen cases from a single institution. Circulation 2008;118:1268.
232. Ricker K, Koch MC, Lehmann-Horn F, et al. Proximalmyotonic myopathy:clinical features of a multisystemdisorder similar to myotonic dystrophy. Arch Neurol 1995;52:25.
233. Milunsky JM, Skare JC, Milunsky A. Presymptomaticdiagnosis of myotonic muscular dystrophy with linkedDNA probes. Am J Med Sci 1991;301:231.
234. Harper PS. Practical genetic counseling, 2nd edn.Bristol:John Wright, 1984.
235. Lenke RR, Levy HL. Maternal phenylketonuria andhyperphenylalaninemia. N Engl J Med 1980;303:1202.
236. van Spronsen FJ, Burgard P. The truth of treatingpatients with phenylketonuria after childhood:the needfor a new guideline. J Inherit Metab Dis 2008;31:673.
237. Gillet D, de Braekeleer M, Bellis G, et al. Cystic fibrosisand pregnancy:report from French data (1980-1999). Br J Obstet Gynaecol 2002;109:912.
238. Odegaard I, Stray-Pedersen B, Hallberg K, et al. Maternaland fetal morbidity in pregnancies of Norwegianand Swedish women with cystic fibrosis. Acta ObstetGynecol Scand 2002;81:698.
239. Gilljam M, Antoniou M, Shin J, et al. Pregnancy in cysticfibrosis:fetal and maternal outcome. Chest 2000;118:85.
240. Kelly TE, Edwards P, Rein M, et al. Teratogenicity ofanticonvulsant drugs. II. A prospective study. Am JMed Genet 1984;19:435.
241. Milunsky A, Alpert E, Kitzmiller JL, et al. Prenatal diagnosisof neural tube defects. VIII. The importance ofserum alpha-fetoprotein screening in diabetic pregnantwomen. Am J Obstet Gynecol 1982;142:1030.
242. Miller E, Hare JW, Cloherty JP, et al. Elevated maternal HbA1c in early pregnancy and major congenital anomaliesin in fants of diabetic mothers. N Engl J Med 1981;304:1331.
243. McElvy SS, Miodovnik M, Rosenn B, et al. A focusedpreconceptional and early pregnancy program inwomen with type 1 diabetes reduces perinatal mortalityand malformation rates to general populationlevels. J Matern Fetal Med 2000;9:14.
244. Penney GC, Mair G, Pearson DW, et al. Outcomes ofpregnancies in women with type 1 diabetes in Scotland:a national population-based study. Br J Obstet Gynaecol 2003;110:315.
245. Rudnik-Schöneborn S, Glauner B, Röhrig D, et al. Obstetric aspects in women with facioscapulohumeralmuscular dystrophy, limb-girdle muscular dystrophyand congenital myopathies. Arch Neurol 1997;54:888.
246. Frank JP, Harati Y, Butler IJ, et al. Central core diseaseand malignant hyperthermia syndrome. Ann Neurol 1980;7:11.
247. World Health Organization. Towards more objectivityin diagnosis and management of male infertility. Int JAndrol 1987;7:1.
248. Scriver CR, Beaudet AL, Sly WS, et al. The metabolicand molecular bases of inherited disease, vol. II, 7thedn. New York:McGraw-Hill, 1995:B 3008.
249. Turnpenny PD, Gunasegaran R, Smith NC, et al. Recurrent miscarriage, cystic hygroma and incontinentiapigmenti. Br J Obstet Gynaecol 1992;99:920.
250. Middeldorp S. Thrombophilia and pregnancy complications:cause or association? J Thromb Haemost 2007;5(suppl 1):276.
251. Bolor H, Mori T, Nishiyama S, et al. Mutations of the SYCP3 gene in women with recurrent pregnancy loss. Am J Hum Genet 2009;84:14.
252. Anguiano A, Oates RD, Amos JA, et al. Congenitalbilateral absence of the vas deferens:a primarily genitalform of cystic fibrosis. JAMA 1992;267:1794.
253. Taulan M, Girardet A, Guittard C, et al. Large genomicrearrangements in the CFTR gene contribute toCBAVD. BMC Med Genet 2007;8:22.
254. Traystman MD, Schulte NA, MacDonald M, et al. Mutation analysis for cystic fibrosis to determinecarrier status in 167 sperm donors from the NebraskaGenetic Semen Bank. Hum Mutat 1994;4:271.
255. Augarten A, Yahav Y, Kerem BS, et al. Congenital bilateralabsence of vas deferens in the absence of cysticfibrosis. Lancet 1994;344:1473.
256. Temple-Smith PD, Southwick GJ, Yates CA, et al. Human pregnancy by IVF using sperm aspirated fromthe epididymis. J In Vitro Fertil Embryo Transfer 1985;2:119.
257. Silber SJ, Ord T, Balmaceda J, et al. Congenital absenceof the vas deferens:the fertilizing capacity of humanepididymal sperm. N Engl J Med 1990;7:147.
258. Reijo R, Lee TY, Salo P, et al. Diverse spermatogeniceffects in humans caused by Y chromosome deletionsencompassing a novel RNA-binding protein gene. NatGenet 1995;10:383.
259. Najmabadi H, Huang V, Yen P, et al. Substantialprevalence of microdeletions of the Y chromosome ininfertile men with idiopathic azoospermia and oligospermiadetected using a sequence-tagged site-basedmapping strategy. J Clin Endocrinol Metab 1996;71:1347.
260. Ma K, Inglis JD, Sharkey A, et al. A Y chromosomegene family with RNA-binding protein homology:candidatesfor the azoospermia factor AZF controllinghuman spermatogenesis. Cell 1993;73:1287.
261. Reijo R, Alagappan RK, Patrizio P, et al. Severe oligozoospermiaresulting from deletions of azoospermiafactor gene on Y chromosome. Lancet 1996;347:1290.
262. deKretser DM. Male infertility. Lancet 1997;349:787.
263. Bonduelle M, Hamberger L, Joris H, et al. Assistedreproduction by intracytoplasmic sperm injection:anESHRE survey of clinical experiences until December1993. Hum Reprod Update 1995;1:3.
264. Meschede D, Horst J. Sex chromosomal anomalies inpregnancies conceived through intracytoplasmicsperm injection:a case for genetic counseling. HumReprod 1997;12:1125.
265. Chandley AC. Meiotic studies and fertility in humantranslocation carriers. In:Daniel A, ed. The cytogeneticsof mammalian autosomal rearrangements. NewYork: Alan R. Liss, 1988:370.
266. Dohle GR, Halley DJ, van Hemel JO, et al. Genetic riskfactors in infertile men with severe oligozoospermiaand azoospermia. Hum Reprod 2002;17:13.
267. Milunsky A. Your genetic destiny:know your genes,secure your health, save your life. Cambridge, UK:Perseus Books, 2001.
268. Prence EM, Jerome CA, Triggs-Raine BL, et al. Heterozygosityfor Tay-Sachs and Sandhoff diseases amongMassachusetts residents with French Canadian background. J Med Screen 1997;4:133.
269. Palomaki GE, Williams J, Haddow JE, et al. Tay-Sachsdisease in persons of French-Canadian heritage innorthern New England. Am J Med Genet 1995;56:409.
270. American Society of Human Genetics. Statement of the American Society of Human Genetics on cystic fibrosiscarrier screening. Am J Hum Genet 1992;51:1443.
271. National Institutes of Health Consensus DevelopmentConference Statement. Bethesda, MD:National Institutesof Health, 1997.
272. Denayer L, Welkenhuysen M, Evers-Kiebooms G, et al. Risk perception after CF carrier testing and impact ofthe test result on reproductive decision making. Am J Med Genet 1997;69:422.
273. Henneman L, Bramsen I, van der Ploeg HM, et al. Preconception cystic fibrosis carrier couple screening:impact, understanding and satisfaction. Genet Test 2003;6:195.
274. Pinckers A. X-linked progressive cone dystrophy. DocOphthalmol Proc Ser 1982;33:399.
275. El-Deiry SS, Naidu S, Blevins LS, et al. Assessmentof adrenal function in women heterozygous for adrenoleukodystrophy. J Clin Endocrinol Metab 1997;82:856.
276. Menage P, Carreau V, Tourbah A, et al. Les adrenoleucodystrophiesheterozygotes symptomatiques del'adulte:10 cas. Rev Neurol 1993;149:445.
277. Gibbons RJ, Suthers GK, Wilkie AOM, et al. X-linkedalpha-thalassemia/mental retardation (ATR-X) syndrome:location to Xq12-q21.31 by X inactivation andlinkage analysis. Am J Hum Genet 1992;51:1136.
278. Hasstedt SJ, Atkin CL, San Juan AC Jr. Genetic heterogeneityamong kindreds with Alport syndrome. Am J Hum Genet 1986;38:940.
279. Patel RR, Hovijitra S, Kafrawy AH, et al. X-linked(recessive) hypomaturation amelogenesis imperfecta:aprosthodontic, genetic and histopathologic report. JProsthet Dent 1991;66:398.
280. Hennekam RCM, Barth PG, van Lookeren CampagneW, et al. A family with severe X-linked arthrogryposis. Eur J Pediatr 1991;150:656.
281. Mathews KD, Ardinger HH, Nishimura DY, et al. Linkage localization of Borjeson-Forssman-Lehmannsyndrome. Am J Med Genet 1989;34:470.
282. Karna J. Choroideremia:a clinical and genetic study of84 Finnish patients and 126 female carriers. Acta Ophthalmol 1986;176(suppl):1.
283. Romera MG, Martin MM, Gonzalez E. Chronic granulomatousdisease:a case study of a symptomatic carrier. J Invest Allerg Clin Immunol 1997;7:57.
284. Lovas JG, Issekutz A, Walsh N, et al. Lupus erythematosus-like oral mucosal and skin lesions in a carrier ofchronic granulomatous disease:chronic granulomatousdisease carrier genodermatosis. Oral Surg OralMed Oral Pathol Oral Rad Endod 1995;80:78.
285. Rollnick BR, Kaye CI. Mendelian inheritance of isolatednonsyndromic cleft palate. Am J Med Genet 1986;24:465.
286. Cremers CWRJ, Huygen PLM. Clinical features offemale heterozygotes in the X-linked mixed deafnesssyndrome (with perilymphatic gusher during stapessurgery). Int J Pediatr Otorhinolaryngol 1983;6:179.
287. Walsh FB, Wegman ME. Pedigree of hereditary cataract,illustrating sex-limited type. Bull Johns HopkinsHosp 1937;61:125.
288. Politano L, Nigro V, Nigro G, et al. Development ofcardiomyopathy in female carriers of Duchenne andBecker muscular dystrophies. JAMA 1996;275:1335.
289. Matthews PM, Benjamin D, van Bakel I, et al. MuscleX-inactivation patterns and dystrophin expression inDuchenne muscular dystrophy carriers. NeuromusculDisord 1995;5:209.
290. Azofeifa J, Voit T, Hubner C, et al. X-chromosomemethylation in manifesting and healthy carriers of dystrophinopathies:concordance of activation ratiosamong first degree female relatives and skewed inactivationas cause of the affected phenotypes. Hum Genet 1995;96;167.
291. Schnur RE, Heymann WR. Reticulate hyperpigmentation. Semin Cutan Med Surg 1997;16:72.
292. Emery AEH. Emery-Dreifuss syndrome. J Med Genet 1989;26:637.
293. Ropers HH, Wienker TF, Grimm T, et al. Evidence forpreferential X-chromosome inactivation in a familywith Fabry disease. Am J Hum Genet 1977;29:361.
294. Thompson EM, Baraitser M, Lindenbaum RH, et al. The FG syndrome:seven new cases. Clin Genet 1985;27:582.
295. Vianna-Morgante AM, Costa SS, Pares AS, et al. FRAXA premutation associated with prematureovarian failure. Am J Med Genet 1996;64:373.
296. Sobesky WE, Taylor AK, Pennington BF, et al. Molecular/clinical correlations in females with fragile X. Am JMed Genet 1996;64:340.
297. Franke P, Maier W, Hautzinger M, et al. Fragile-Xcarrier females:evidence for a distinct psychopathologicalphenotype ? Am J Med Genet 1996;64:334.
298. Meloni T, Forteleoni G, Dore A, et al. Neonatal hyperbilirubinaemiain heterozygous glucose-6-phosphatedehydrogenase deficient females. Br J Haematol 1983;53:241.
299. Mauser Bunchoten EP, van Houwelingen JC,Sjamsoedin Visser EJ, et al. Bleeding symptoms in carriersof hemophilia A and B. Thromb Haemost 1988;59:349.
300. Vabres P, Larregu M. X-linked genodermatoses. AnnDermatol Venereol 1995;122:154.
301. Endres W. Inherited metabolic diseases affecting thecarrier. J Inherit Metab Dis 1997;20:9.
302. Lorette G, Toutain A, Barthes M, et al. Menkes syndrome:an unusual pigmentation anomaly in a motherand three sisters. Ann Pediatr 1992;39:453.
303. Collie WR, Moore CM, Goka TJ, et al. Pili torti asmarker for carriers of Menkes disease. Lancet 1978;1:607.
304. Bartsocas CS, Kastrantas AD. X-linked form of myopia. Hum Hered 1981;31:199.
305. Nance WE, Warburg M, Bixler D, et al. CongenitalX-linked cataract, dental anomalies and brachymetacarpalia. Birth Defects Orig Artic Ser 1974;10:285.
306. Kellner U, Fuchs S, Bornfeld N, et al. Ocular phenotypesassociated with two mutations (R121W, C126X)in the Norrie disease gene. Ophthalmol Genet 1996;17:67.
307. Charles SJ, Moore AT, Zhang Y, et al. Carrier detectionin X linked ocular albinism using linked DNA polymorphisms.Br J Ophthalmol 1994;78:539.
308. Erpenstein H, Pfeiffer RA. Geschlechsgebundendominanterbliche Zahnunterzahl. Humangenetik 1967;4:280.
309. Herinklake S, Boker K, Manns M. Fatal clinicalcourse of ornithine transcarbamylase deficiency in anadult heterozygous female patient. Digestion 1977;58:83.
310. Fries MH, Kuller JA, Jurecki E, et al. Prenatal counselingin heterozygotes for ornithine transcarbamylasedeficiency in an adult heterozygous female patient. Digestion 1997;58:83.
311. Kaplan J, Pelet A, Hentari H, et al. Contribution tocarrier detection and genetic counseling in X linkedretinoschisis. J Med Genet 1991;28:383.
312. Souied E, Segues B, Ghazi I, et al. Severe manifestationsin carrier females in X linked retinitis pigmentosa. JMed Genet 1997;34:793.
313. Harris JW, Danish EH, Brittenham GM, et al. Pyridoxineresponsive hereditary sideroblastic erythropoiesisand iron overload:two microcytic subpopulations inthe affected male, one normocytic and one microcyticsubpopulation in the obligate female carrier. Am JHematol 1993;42:400.
314. McKusick VA. Mendelian inheritance in man, 11thedn. Baltimore, MD:Johns Hopkins University Press,1994:2530.
315. Ahmad M, Abbas H, Haque S, et al. X-chromosomallyinherited split-hand/split foot anomaly in a Pakistanikindred. Hum Genet 1987;75:169.
316. McKusick VA. Mendelian inheritance in man, 11thedn. Baltimore, MD:Johns Hopkins University Press,1994:2535.
317. van den Berghe H, Dequeker J, Fryns JP, et al. Familialoccurrence of severe ulnar aplasia and lobster claw feet:a new syndrome. Hum Genet 1978;42:109.
318. Wengler G, Gorlin JB, Williamson JM, et al. Nonrandominactivation of the X chromosome in early lineagehematopoietic cells in carriers of Wiskott-Aldrich syndrome. Blood 1995;85:2471.
319. Peacocke M, Siminovitch KA. The Wiskott-Aldrichsyndrome. Semin Dermatol 1993;12:247.
320. Stoll C, Geraudel A, Chauvin A. New X-linked syndromeof mental retardation, short stature and hypertelorism. Am J Med Genet 1991;39:474.
321. Atkin JF, Flaitz K, Patil S, et al. A new X-linked mentalretardation syndrome. Am J Med Genet 1985;21:697.
322. Nowakowski R. Ocular manifestations in female carriersof X-linked disorders. J Am Optom Assoc 1995;66:352.
323. Politano L, Nigro V, Nigro G, et al. Development ofcardiomyopathy in female carriers of Duchenne andBecker muscular dystrophies. JAMA 1996;275:1335.
324. American Academy of Pediatrics, Section on Cardiologyand Cardiac Surgery. Cardiovascular health supervisionfor individuals affected by Duchenne or Beckermuscular dystrophy. Pediatrics 2005;116:1569.
325. Bobo JK, Kenneson A, Kolor K, et al. Adherence toAmerican Academy of Pediatrics recommendations forcardiac care among female carriers of Duchenne andBecker muscular dystrophy. Pediatrics 2009;123:471.
326. de Vries BB, van den Boer-van den Berg HM, Niermeijer MF, et al. Dilemmas in counseling females with thefragile X syndrome. J Med Genet 1999;36:167.
327. Simioni P, Prandoni P, Lensing AW, et al. The risk ofrecurrent venous thromboembolism in patients withan Arg5066Gln mutation in the gene for factor V(factor V Leiden). N Engl J Med 1997;336:399.
328. Brenner B, Blumenfeld Z. Thrombophilia and fetalloss. Blood Rev 1997;11:72.
329. Bear JC, Parfrey PS, Morgan JM, et al. Autosomaldominant polycystic kidney disease:new informationfor genetic counseling. Am J Med Genet 1992;43:539.
330. Veldhuisen B, Saris JJ, deHaij S, et al. A spectrum ofmutations in the second gene for autosomal dominantpolycystic kidney disease (PKD2). Am J Hum Genet 1997;61:547.
331. Neyroud N, Tesson F, Denjoy I, et al. A novel mutationin the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet 1997;15:186.
332. Gorry MC, Gabbaizedeh D, Furey W, et al. Mutationsin the cationic trypsinogen gene are associated withrecurrent acute and chronic pancreatitis. Gastroenterology 1997;113:1063.
333. Witt H, Luck W, Hennies HC, et al. Mutations in thegene encoding the serine protease inhibitor, Kazal type1 are associated with chronic pancreatitis. Nat Genet 2000;25:213.
334. Rebours V, Boutron-Ruault MC, Schnee M, et al. Thenatural history of hereditary pancreatitis:a nationalseries. Gut 2009;58:97.
335. Ryynänen Markku, Kirkinen P, Mannermaa A,et al. Carrier diagnosis of the fragile X syndrome:achallenge in antenatal clinics. Am J Obstet Gynecol 1995;172:1236.
336. Mornet E, Chateau C, Taillandier A, et al. Recurrentand unexpected segregation of the FMR1 CGG repeatin a family with fragile X syndrome. Hum Genet 1996;97:512.
337. Abdulrazzaq YM, Bener A, Al-Gazali LI, et al. A studyof possible deleterious effects of consanguinity. ClinGenet 1997;51:167.
338. Saadallah AA, Rashed MS. Newborn screening:experiencesin the Middle East and North Africa. J InheritMetab Dis 2007;30:482.
339. Bundey S, Alam H, Kaur A, et al. Race, consanguinityand social features in Birmingham babies:a basis forprospective study. J Epidemiol Commun Health 1990;44:130.
340. Khoury SA, Massad DF. Consanguinity, fertility,reproductive wastage, infant mortality and congenitalmalformations in Jordan. Saudi Med J 2000;21:150.
341. Stoltenberg C, Magnus P, Lie RT, et al. Birth defectsand parental consanguinity in Norway. Am J Epidemiol 1997;145:439.
342. Perveen F, Tyyab S. Frequency and pattern of distributionof congenital anomalies in the newborn and associatedmaternal risk factors. J Coll Physicians Surg Pak 2007;17:340.
343. Chudley AE. Fetal alcohol spectrum disorder:countingthe invisible-mission impossible? Arch Dis Child 2008;93:721.
344. Clarren SK, Randels SP, Sanderson M, et al. Screeningfor fetal alcohol syndrome in primary schools:a feasibilitystudy. Teratology 2001;63:3.
345. Milunsky A, Ulcickas M, Rothman KJ, et al. Maternalheat exposure and neural tube defects. JAMA 1992;268:882.
346. Martinez-Frias ML, Bermejo E, Rodriguez-Pinilla E,et al. Periconceptional exposure to contraceptive pillsand risk for Down syndrome. J Perinatol 2001;21:288.
347. Reilly PR, Milunsky A. Medicolegal aspects of prenataldiagnosis. In:Milunsky A, ed. Genetic disorders andthe fetus:diagnosis, prevention and treatment. NewYork: Plenum Press, 1979:603.
348. Milunsky A. Genetic disorders and the fetus:diagnosis,prevention and treatment. New York:Plenum Press,1979.
349. NICHD National Registry for Amniocentesis StudyGroup. Midtrimester amniocentesis for prenatal diagnosis:safety and accuracy. JAMA 1976;236:1471.
350. Simpson NE, Dallaire L, Miller JR, et al. Prenatal diagnosisof genetic disease in Canada:report of a collaborativestudy. Can Med Assoc J 1976;115:739.
351. International Huntington Association and World Federationof Neurology. Guidelines for the moleculargenetics predictive test in Huntington's disease. Neurology 1994;44:1533.
352. Tibben A, Duivenvoorden J, Niermeijer MF, et al. Psychologicaleffects of presymptomatic DNA testing forHuntington's disease in the Dutch program. PsychosomMed 1994;56:526.
353. Lawson K, Wiggins S, Green T, et al. Adverse psychologicalevents occurring in the first year after predictivetesting for Huntington's disease. J Med Genet 1996;33:856.
354. Wiggins S, Whyte P, Huggins M, et al. The psychologicalconsequences of predictive testing for Huntington'sdisease. N Engl J Med 1992;327:1401.
355. Evers-Kiebooms G, Nys K, Harper P, et al. PredictiveDNA-testing for Huntington's disease and reproductivedecision making:a European collaborative study. Eur J Hum Genet 2002;10:167.
356. Perry TL. Some ethical problems in Huntington'schorea. Can Med Assoc J 1981;125:1098.
357. Quaid KA, Brandt J, Faden RR, et al. Knowledge, attitudeand the decision to be tested for Huntington'sdisease. Clin Genet 1989;36:431.
358. Evers-Kiebooms G, Swerts A, Cassimann JJ, et al. Themotivation of at-risk individuals and their partners indeciding for or against predictive testing for Huntington's disease. Clin Genet 1989;35:29.
359. Sorenson SA, Fenger K. Suicide in patients with Huntington's disease and their sibs. Am J Hum Genet 1991;49:316.
360. Schoenfeld M, Myers RH, Cupples LA, et al. Increasedrate of suicide among patients with Huntington'sdisease. J Neurol Neurosurg Psychiatry 1984;47:1283.
361. Almqvist EW, Bloch M, Brinkman R, et al, on behalfof an International Huntington Disease CollaborativeGroup. A worldwide assessment of the frequency ofsuicide, suicide attempts or psychiatric hospitalizationafter predictive testing for Huntington disease. Am JHum Genet 1999;64:1293.
362. Markel DS, Young AB, Penney JB. At-risk persons'attitudes toward presymptomatic and prenatal testingof Huntington's disease in Michigan. Am J Med Genet 1987;26:295.
363. Lamport AN. Presymptomatic testing for Huntington's chorea:ethical and legal issues. Am J Med Genet 1987;26:307.
364. Taylor CA, Myers RH. Long-term impact of Huntingtondisease linkage testing. Am J Med Genet 1997:70:365.
365. Hayden MR. Predictive testing for Huntington disease:are we ready for widespread community implementation? Am J Med Genet 1991;40:515.
366. Nance MA, Leroy BS, Orr HT, et al. Protocol forgenetic testing in Huntington disease:three years ofexperience in Minnesota. Am J Med Genet 1991;40:518.
367. Decruyenaere M, Evers-Kiebooms G, Cloostermans T,et al. Psychological distress in the 5-year period afterpredictive testing for Huntington's disease. Eur J HumGenet 2003;11:30.
368. Evans DGR, Maher EF, Macleod R, et al. Uptake ofgenetic testing for cancer predisposition. J Med Genet 1997;34:746.
369. Deltas CC, Christodoulou K, Tjakouri C, et al. Presymptomatic molecular diagnosis of autosomaldominant polycystic kidney disease using PKD1-and PKD2-linked markers in Cypriot families. Clin Genet 1996;50:10.
370. Pirson Y, Chaveau D. Intracranial aneurysms in autosomaldominant polycystic kidney disease. In:WatsonML, Torres VE, eds. Polycystic kidney disease. Oxford:Oxford University Press, 1996:530.
371. Sujansky E, Kreutzer SB, Johnson AM, et al. Attitudesof at-risk and affected individuals regarding presymptomatictesting for autosomal dominant polycystickidney disease. Am J Med Genet 1990;35:510.
372. Hannig VL, Hopkins JR, Johnson HK, et al. Presymptomatictesting for adult onset polycystic kidney diseasein at-risk kidney transplant donors. Am J Med Genet 1991;40:425.
373. Giardiello FM, Brensinger JD, Petersen GM, et al. Theuse and interpretation of commercial APC gene testingfor familial adenomatous polyposis. N Engl J Med 1997;336:823.
374. Telander RL, Zimmerman D, Sizemore GW, et al. Medullary carcinoma in children:results of earlydetection and surgery. Arch Surg 1989;124:841.
375. Ross LF. Predictive genetic testing for conditions thatpresent in childhood. Kennedy Inst Ethics J 2002;12:225.
376. Wertz DC, Fanos JH, Reilly PR. Genetic testing forchildren and adolescents:who decides? JAMA 1994;272:875.
377. Milunsky JM, Maher TA, Loose BA, et al. XL PCR forthe detection of large trinucleotide expansions in juvenileHuntington's disease. Clin Genet 2003;64:70.
378. Tassicker R, Savulescu J, Skene L, et al. Prenataldiagnosis requests for Huntington's disease when thefather is at risk and does not want to know his geneticstatus:clinical, legal and ethical viewpoints. BMJ 2003;326:331.
379. Gusella JF, McNeil S, Persichetti F, et al. Huntington'sdisease. Cold Spring Harb Symp Quant Biol 1996;61:615.
380. Kremer B, Goldberg P, Andrew SE., A worldwide studyof the Huntington's disease mutation:the sensitivityand specificity of measuring CAG repeats. N Engl J Med 1994;330:1401.
381. Alonso ME, Yescas P, Rasmussen A, et al. Homozygosityin Huntington's disease:new ethical dilemmacaused by molecular diagnosis. Clin Genet 2002;61:437.
382. Lancaster JM, Wiseman RW, Berchuck A. An inevitabledilemma:prenatal testing for mutations in theBRCA1 breast-ovarian cancer susceptibility gene. Obstet Gynecol 1996;87:306.
383. DudokdeWit AC, Tibben A, Frets PG, et al. BRCA1 inthe family:a case description of the psychologicalimplications. Am J Med Genet 1997;71:63.
384. Julian-Reynier C, Eisinger F, Vennin P, et al. Attitudestowards cancer predictive testing and transmission ofinformation to the family. J Med Genet 1996;33:731.
385. Lancaster JM, Wiseman RW, Berchuck A. An inevitabledilemma:prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene. Obstet Gynecol 1996;87:306.
386. Antoniou A, Pharoah PD, Narod S, et al. Average risksof breast and ovarian cancer associated with BRCA1 orBRCA2 mutations detected in case series unselected forfamily history:a combined analysis of 22 studies. AmJ Hum Genet 2003;72:1117.
387. National Comprehensive Cancer Network. Practiceguidelines in oncology. Genetic/familial high-riskassessment:breast and ovarian. Version 1. Fort Washington,PA:National Comprehensive Cancer Network,2008.375. Burke W, Daly M, Garber J, et al. Recommendationsfor follow-up care of individuals with an inherited predispositionto cancer. II. BRCA1 and BRCA2. CancerGenetics Studies Consortium. JAMA 1997;277:997.
388. King M-C, Marks JH, Mandell JB. Breast and ovariancancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003:302;643.
389. Laken SJ, Petersen GM, Gruber SB, et al. Familialcolorectal cancer in Ashkenazim due to a hypermutabletract in APC. Nat Genet 1997;17:79.
390. Warburton D, Kline J, Stein Z, et al. Does the karyotypeof a spontaneous abortion predict the karyotype of asubsequent abortion? Evidence from 273 women withtwo karyotyped spontaneous abortions. Am J HumGenet 1987;41:465.
391. Campuzano V, Montermini L, Molot MD, et al. Friedreich's ataxia:autosomal recessive disease caused byan intronic GA triplet repeat expansion. Science 1996;271:1423.
392. Jaspert A, Fahsold R, Grehl H, et al. Myotonic dystrophy:correlation of clinical symptoms with the size ofthe CTG trinucleotide repeat. J Neurol 1995;242:99.
393. Kalousek DK, Barrett I. Genomic imprinting related toprenatal diagnosis. Prenat Diagn 1994;14:1191.
394. Deal CL. Parental genomic imprinting. Curr OpinPediatr 1995;7:445.
395. Clayton-Smith J, Laan L. Angelman syndrome:are view of the clinical and genetic aspects. J Med Genet 2003;40:87.
396. Dindot SV, Antaiffy BA, Bhattacharjee MB, et al. TheAngelman syndrome ubiquitin ligase localizes to thesynapse and nucleus and maternal deficiency results inabnormal dendritic spine morphology. Hum MolGenet. 2008;17:111.
397. Walter J, Paulsen M. Imprinting and disease. SeminCell Dev Biol 2003;14:101.
398. Rossignol S, Steunou V, Chalas C, et al. The epigeneticimprinting defect of patients with Beckwith-Wiedemannsyndrome born after assisted reproductive technologyis not restricted to the 11p15 region. J MedGenet 2006;43:902.
399. Wilkins-Haug L, Porter A, Hawley P, et al. Isolatedfetal omphalocele, Beckwith-Wiedemann syndromeand assisted reproductive technologies. Birth DefectsRes A Clin Mol Teratol 2009;85:58.
400. Barel O, Shalev SA, Ofir R, et al. Maternally inheritedBirk Barel mental retardation dysmorphism syndromecaused by a mutation in the genomically imprintedpotassium channel KCNK9. Am J Hum Genet 2008;83:193.
401. Fournet JC, Mayaud C, de Lonlay P, et al. Loss ofimprinted genes and paternal SUR1 mutations lead tofocal form of congenital hyperinsulinism. Horm Res 2000;53:2.
402. Passos-Bueno MR, Cerqueira A, Vainzof M, et al. My otonicdystrophy:genetic, clinical and molecular analysisof patients from 41 Brazilian families. J Med Genet 1995;32:14.
403. Judson H, Hayward BE, Sheridan E, et al. A global disorder of imprinting in the human female germ line. Nature 2002;416:539.
404. van Schothorst EM, Jansen JC, Bardoel AF, et al. Confinement of PGL, an imprinted gene causing hereditaryparagangliomas, to a 2-cM interval on 11q22-q23 andexclusion of DRD2 and NCAM as candidate genes. EurJ Hum Genet 1996;4:267.
405. Muller B, Hedrich K, Kock N, et al. Evidence thatpaternal expression of the epsilon-sarcoglycan geneaccounts for reduced penetrance in myoclonus-dystonia. Am J Hum Genet 2002;71:1303.
406. Fokstuen S, Ginsburg C, Zachmann M, et al. Maternaluniparental disomy 14 as a cause of intrauterinegrowth retardation and early onset of puberty. J Pediatr 1999;134:689.
407. Eggermann T, Zerres K, Eggermann K, et al. Uniparentaldisomy:clinical indications for testing in growthretardation. Eur J Pediatr 2002;161:305.
408. Davies W, Isles AR, Wilkinson LS. Imprinted genes andmental dysfunction. Ann Med 2001;33:428.
409. Perk J, Makedonski K, Lande L, et al. The imprintingmechanism of the Prader-Willi/Angelman regionalcontrol center. EMBO J 2002;21:5807.
410. Bastepe M, Juppner H. Pseudohypoparathyroidism:new insights into an old disease. Endocrinol MetabClin North Am 2000;29:569.
411. Shore EM, Ahn J, Jan de Beur S, et al. Paternally inheritedinactivating mutations of the GNAS1 gene in progressiveosseous heteroplasia. N Engl J Med 2002;346:99.
412. Balmer D, Arredondo J, Samaco RC, et al. MECP2mutations in Rett syndrome adversely affect lymphocytegrowth but do not affect imprinted geneexpression in blood or brain. Hum Genet 2002;110:545.
413. Girard M, Couvert P, Carrie A, et al. Parental origin ofde novo MECP2 mutations in Rett syndrome. Eur JHum Genet 2001;9:231.
414. Hitchins MP, Stanier P, Preece MA, et al. Silver-Russellsyndrome:a dissection of the genetic aetiology and candidatechromosomal regions. J Med Genet 2001;38:810.
415. Netchine I, Rossignol S, Dufourg MN, et al. 11p15imprinting center region 1 loss of methylation is acommon and specific cause of typical Russell-Silversyndrome:clinical scoring system and epigenetic-phenotypic correlations. J Clin Endocrinol Metab 2007;92:3148.
416. Hannula K, Lipsanen-Nyman M, Kristo P, et al. Genetic screening for maternal uniparental disomy ofchromosome 7 in prenatal and postnatal growth retardationof unknown cause. Pediatrics 2002;109:441.
417. Temple IK, Shield JP. Transient neonatal diabetes, adisorder of imprinting. J Med Genet 2002;39:872.
418. Mackay DJ, Boonen SE, Clayton-Smith J, et al. Amaternal hypomethylation syndrome present as transientneonatal diabetes mellitus. Hum Genet 2006;120:262.
419. Amor DJ, Halliday J. A review of known imprintingsyndromes and their associtation with assisted reproductiontechnologies. Hum Reprod 2008;23:2826.
420. Turpin JC. Huntington chorea in children. Arch FrPediatr 1993;50:119.
421. Thorisson GA, Muilu J, Brookes AJ. Genotypephenotypedatabases:challenges and solutions for thepost-genomic era. Nat Rev Genet 2009;10:9.
422. Pyeritz RE, McKusick VA. The Marfan syndrome:diagnosis and management. N Engl J Med 1979;300:772.
423. Beutler E, Nguyen NJ, Henneberger MW, et al. Gaucher disease:gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet 1993;53:85.
424. Lewis BD, Nelson PV, Robertson EF, et al. Mutationanalysis of 28 Gaucher disease patients:the Australasianexperience. Am J Med Genet 1994;49:218.
425. Kerem E, Corey M, Kerem B, et al. The relationshipbetween genotype and phenotype in cystic fibrosis:analysis of the most common mutation. N Engl J Med 1990;323:1517.
426. Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype inpatients with cystic fibrosis. N Engl J Med 1993;329:1308.
427. Dork T, Wulbrand U, Richter T, et al. Cystic fibrosiswith three mutations in the cystic fibrosis transmembraneregulator gene. Hum Genet 1991;87:441.
428. Le C, Ramjeesingh M, Reys E, et al. The cystic fibrosismutation (F508) does not influence the chloridechannel activity of CFTR. Nat Genet 1993;3:311.
429. Tuddenham EGD. Factor VIII and haemophilia A. Bailli ère's Clin Haematol 1989;2:849.
430. Miller DS, Steinbrecher RA, Wieland K, et al. Themolecular genetic analysis of haemophilia A:characterizationof six partial deletions in the factor VIII gene. Hum Genet 1990;86:219.
431. Hoo JJ. Alternative explanations for recurrent achondroplasiain siblings with normal parents. Clin Genet 1984;25:553.
432. Bakker E, Veenema H, Den Dunnen JT, et al. Germinalmosaicism increases the recurrence risk for "new"Duchenne muscular dystrophy mutations. J MedGenet 1989;26:553.
433. Donnai D, Read AP, McKeown C, et al. Hypomelanosisof Ito-A manifestation of mosaicism or chimerism. J Med Genet 1988;25:809.
434. Thomas IT, Frias JL, Cantu ES, et al. Association ofpigmentary anomalies with chromosomal and geneticmosaicism and chimerism. Am J Hum Genet 1989;45:193.
435. Raghunath M, Mackay K, Dalgleish R, et al. Geneticcounseling on brittle grounds:recurring osteogenesisimperfecta due to parental mosaicism for a dominantmutation. Eur J Pediatr 1995;154:123.
436. Lund AM, Nicholls AC, Schwartz M, et al. Parentalmosaicism and autosomal dominant mutationscausing structural abnormalities of collagen I are frequentin families with osteogenesis imperfecta type III/IV. Acta Paediatr 1997;86:711.
437. Telenius H, Kremer B, Goldberg YP, et al. Somatic andgonadal mosaicism of the Huntington disease geneCAG repeat in brain and sperm. Nat Genet 1994;6:409.
438. Cancel G, Durr A, Didierjean O, et al. Molecular andclinical correlations in spinocerebellar ataxia 2:a studyof 32 families. Hum Mol Genet 1997;6:709.
439. Satge D, Geneix A, Goburdhun J, et al. A history ofmiscarriages and mild prognathism as possible modeof presentation of mosaic trisomy 18 in women. ClinGenet 1996;50:470.
440. Ptacek JT, Eberhardt TL. Breaking bad news. JAMA 1996;276:496.
441. Bond CF, Anderson EL. The reluctance to transmit badnews:private discomfort or public display? J Eur Soc Psychol 1987;23:176.
442. Robyr R, Bernard JP, Roume J, et al. Familial diseasesrevealed by a fetal anomaly. Prenat Diagn 2006;26:1224.
443. White-van Mourik MCA, Connor JM, Ferguson-SmithMA. The psychosocial sequelae of a second-trimestertermination of pregnancy for fetal abnormality. PrenatDiagn 1992;12:189.
444. Blumberg BD, Golbus MC, Hanson K. The psychologicalsequelae of abortion performed for a genetic indication. Am J Obstet Gynecol 1975;122:799.
445. Blumberg BD. The emotional implications of prenataldiagnosis. In:Emery, AEH, Pullen IM, eds. Psychologicalaspects of genetic counselling. London:Academic Press, 1984:202.
446. Parkes CM. Bereavement. Studies of grief in adult life. London:Tavistock Publications, 1972.
447. Worden JW. Grief counseling and grief therapy, 2ndedn. New York:Springer, 1991.
448. Appleton R, Gibson B, Hey E. The loss of a baby atbirth:the role of the bereavement officer. Br J ObstetGynaecol 1993;100:51.
449. Seller M, Barnes C, Ross S, et al. Grief and mid-trimester fetal loss. Prenat Diagn 1993;13:341.
450. Fanos JH. Developmental tasks of childhood and adolescence:implications for genetic testing. Am J MedGenet 1997;71:22.
451. Wertz DC, Fanos JH, Reilly PR. Genetic testing forchildren and adolescents:who decides? JAMA 1994;272:875.
452. Clinical Genetics Society (UK). Report of a WorkingParty:the genetic testing of children. J Med Genet 1994;31:785.
453. American Society of Human Genetics and AmericanCollege of Medical Genetics. Points to consider:ethical,legal and psychosocial implications of genetic testingin children and adolescents. Am J Hum Genet 1995;57:1233.
454. Green M, Solnit AJ. Reactions to the threatened loss ofa child:a vulnerable child syndrome. Pediatrics 1964;34:58.
455. McIntosh N, Eldrige C. Neonatal death:the neglectedside of neonatal care? Arch Dis Child 1984;59:585.
456. Bourne S. The psychological effects of a stillbirth onwomen and their doctors. J R Coll Gen Pract 1968;16:103.
457. Crowther ME. Communication following a stillbirthor neonatal death:room for improvement. Br J ObstetGynaecol 1995;102:952.
458. Brookes JAS, Hall-Craggs MA, Sams VR, et al. Non-invasive perinatal necropsy by magnetic resonanceimaging. Lancet 1996;348:1139.
459. Nicholas AM, Lewin TJ. Grief reactions of parentalcouples:congenital handicap and cot death. Med JAust 1986;144:292.
460. Lewis E, Bryan E. Management of perinatal loss of atwin. BMJ 1988;297:1321.
461. Lewis E. Stillbirth:psychological consequences andstrategies of management. In:Milunsky A, ed. Advancesin perinatal medicine, vol. 3. New York:Plenum,1983:205.
462. McPhee SJ, Bottles K, Lo B, et al. To redeem them fromdeath:reactions of family members to autopsy. Am JMed 1986;80:665.
463. Irvin NA, Kennell JH, Klaus MH. Caring for theparents of an infant with a congenital malformation. In:Warkany J, ed. Congenital malformations:notesand comments. Chicago:Year Book Medical Publishers,1971.
464. Klaus MH, Kennell JH. Caring for parents of an infantwho dies:maternal-infant bonding. St Louis, MO:CVMosby, 1976.
465. Furlong RM, Hobbins JC. Grief in the perinatal period. Obstet Gynecol 1983;61:497.
466. Shulman LP, Grevengood C, Phillips OP, et al. Familyplanning decisions after prenatal detection of fetalabnormalities. Am J Obstet Gynecol 1994;171:1373.
467. Rowe J, Clyman R, Green C, et al. Follow-up of familieswho experience a perinatal death. Pediatrics 1978;62:166.
468. Forrest GC, Standish E, Baum JD. Support after perinataldeath:a study of support and counseling afterbereavement. BMJ 1982;285:1475.
469. Clarke A, Parsons E, Williams A. Outcomes andprocess in genetic counseling. Clin Genet 1996;50:462.
470. Emery AEH, Raeburn JA, Skinner R. Prospective studyof genetic counseling. BMJ 1979;1:253.
471. Sibinga MS, Friedman CG. Complexities of parentalunderstanding for phenylketonuria. Pediatrics 1971;48:216.
472. Reynolds BD, Puck MH, Robinson A. Genetic counseling:an appraisal. Clin Genet 1974;5:177.
473. Sorenson JR, Swazey JP, Scotch NA. Effective geneticcounseling:more informed clients. In:Reproductivepasts, reproductive futures:genetic counseling and it seffectiveness. New York:Alan R. Liss, 1981:79.
474. Aalfs CM, Oort FJ, de Haes JC, et al. A comparison ofcounselee and counselor satisfaction in reproductivegenetic counseling. Clin Genet 2007;72:74.
475. Wertz DC, Sorenson JR, Heeren TC. Clients'interpretationof risks provided in genetic counseling. Am JHum Genet 1986;39:253.
476. Kessler S. Psychological aspects of genetic counseling.VI. A critical review of the literature dealing witheducation and reproduction. Am J Med Genet 1989;34:340.
477. Davey A, Rostant K, Harrop K, et al. Evaluating geneticcounseling:client expectations, psychological adjustmentand satisfaction with service. J Genet Couns2005;14:197.
478. Swerts A. Impact of genetic counseling andprenatal diagnosis for Down syndrome and neuraltube defects. Birth Defects Orig Artic Ser 1987;23 (2):61.